These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33830461)

  • 1. Association of Treatment Intensity and Adherence to Lipid-Lowering Therapy with Major Adverse Cardiovascular Events Among Post-MI Patients in Germany.
    Ahrens I; Khachatryan A; Monga B; Dornstauder E; Sidelnikov E
    Adv Ther; 2021 May; 38(5):2532-2541. PubMed ID: 33830461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: Five years of clinical follow-up from 164,565 post-myocardial infarction patients.
    Schiele F; Quignot N; Khachatryan A; Gusto G; Villa G; Kahangire D; Chauny JV; Ricci L; Desamericq G
    Int J Cardiol; 2021 Jun; 332():22-28. PubMed ID: 33705845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity of and Adherence to Lipid-Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease.
    Mazhar F; Hjemdahl P; Clase CM; Johnell K; Jernberg T; Sjölander A; Carrero JJ
    J Am Heart Assoc; 2022 Jul; 11(14):e025813. PubMed ID: 35861825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of lipid-lowering treatment intensity and adherence on cardiovascular outcomes in patients with a recent myocardial infarction: a Swedish register-based study.
    Svensson MK; Sorio Vilela F; Leósdóttir M; Banefelt J; Lindh M; Dun AR; Norhammar A; Villa G
    Ups J Med Sci; 2022; 127():. PubMed ID: 35722183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.
    Khunti K; Danese MD; Kutikova L; Catterick D; Sorio-Vilela F; Gleeson M; Kondapally Seshasai SR; Brownrigg J; Ray KK
    JAMA Netw Open; 2018 Dec; 1(8):e185554. PubMed ID: 30646277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy.
    Corrao G; Conti V; Merlino L; Catapano AL; Mancia G
    Clin Ther; 2010 Feb; 32(2):300-10. PubMed ID: 20206788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity of and adherence to lipid-lowering therapy as predictors of goal attainment and major adverse cardiovascular events in primary prevention.
    Mazhar F; Hjemdahl P; Sjölander A; Kahan T; Jernberg T; Carrero JJ
    Am Heart J; 2024 Mar; 269():118-130. PubMed ID: 38109988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient characteristics, treatment patterns, and adherence to lipid-lowering therapies following an acute coronary syndrome.
    Bruckert E; Desamericq G; Khachatryan A; Ngo P; Gusto G; Sorio-Vilela F
    Rev Cardiovasc Med; 2020 Dec; 21(4):643-650. PubMed ID: 33388010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid lowering therapy patterns and the risk of cardiovascular events in the 1-year after acute myocardial infarction in United Arab Emirates.
    Pinto L; Farghaly M; Nunna S; Chickballapur Ramachandrachar B; Chilukuri SH; Natarajan A
    PLoS One; 2022; 17(9):e0268709. PubMed ID: 36054205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events.
    Cordero A; Fernández Olmo R; Badimon L; Santos-Gallego CG; Castellano JM; Fácila L; Rodriguez-Manero M; Bonanad C; Vilahur G; Escribano D; Badimon JJ; González-Juanatey JR
    J Clin Lipidol; 2023; 17(5):602-611. PubMed ID: 37775463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction.
    Serban MC; Colantonio LD; Manthripragada AD; Monda KL; Bittner VA; Banach M; Chen L; Huang L; Dent R; Kent ST; Muntner P; Rosenson RS
    J Am Coll Cardiol; 2017 Mar; 69(11):1386-1395. PubMed ID: 28302290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More- Versus Less-Intensive Lipid-Lowering Therapy.
    Toyota T; Morimoto T; Yamashita Y; Shiomi H; Kato T; Makiyama T; Nakagawa Y; Saito N; Shizuta S; Ono K; Kimura T
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005460. PubMed ID: 31412729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study.
    Bang CN; Gislason GH; Greve AM; Torp-Pedersen C; Køber L; Wachtell K
    Eur J Prev Cardiol; 2014 Mar; 21(3):330-8. PubMed ID: 23012689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Implications of Switching Lipid Lowering Treatment from Rosuvastatin to Other Agents in Primary Care.
    Colivicchi F; Gulizia MM; Franzini L; Imperoli G; Castello L; Aiello A; Ripellino C; Cataldo N
    Adv Ther; 2016 Nov; 33(11):2049-2058. PubMed ID: 27671328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis.
    Degli Esposti L; Saragoni S; Batacchi P; Benemei S; Geppetti P; Sturani A; Buda S; Degli Esposti E
    Clin Ther; 2012 Jan; 34(1):190-9. PubMed ID: 22284998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of pre- and posthospital medication adherence in myocardial infarction patients.
    Doll JA; Hellkamp AS; Thomas L; Fonarow GC; Peterson E; Wang TY
    Am Heart J; 2019 Feb; 208():74-80. PubMed ID: 30580129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-myocardial Infarction (MI) Care: Medication Adherence for Secondary Prevention After MI in a Large Real-world Population.
    Huber CA; Meyer MR; Steffel J; Blozik E; Reich O; Rosemann T
    Clin Ther; 2019 Jan; 41(1):107-117. PubMed ID: 30591287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of high-intensity lipid-lowering therapy under-prescription after acute myocardial infarction in women.
    Weizman O; Hauguel-Moreau M; Tea V; Albert F; Barragan P; Georges JL; Delarche N; Kerneis M; Bataille V; Drouet E; Puymirat E; Ferrières J; Schiele F; Simon T; Danchin N;
    Eur J Prev Cardiol; 2024 Nov; 31(15):1850-1860. PubMed ID: 39192488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.